Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam D Devore

Showing results (231-240 of 339) with videos related to

Pageof 34
Sort By:
Journal of Cardiac Failure|November 18, 2021
Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF RegistryStephen J Greene, Javed Butler, Anne S Hellkamp, et al.
Journal of Cardiac Failure|January 24, 2025
Implantable Cardioverter-Defibrillators and Cardiovascular Resynchronization Therapy with Left Ventricular Assist DevicesA MOMENTUM 3 Trial AnalysisGabriel Sayer, Mustafa M Ahmed, Mandeep R Mehra, et al.
American Heart Journal|January 26, 2021
Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbiditiesNancy M Albert, Rachel J Tyson, C Larry Hill, et al.
Journal of the American Heart Association|June 20, 2022
Angiotensin Receptor Neprilysin Inhibition and Associated Outcomes by Race and Ethnicity in Patients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP-HFBrittany Chapman, Anne S Hellkamp, Laine E Thomas, et al.
American Heart Journal|August 10, 2016
Development and validation of a risk model for in-hospital worsening heart failure from the Acute Decompensated Heart Failure National Registry (ADHERE)Adam D DeVore, Melissa A Greiner, Puza P Sharma, et al.
The American Journal of Cardiology|September 4, 2023
Potential Applicability of Omecamtiv Mecarbil to Patients Hospitalized for Worsening Heart FailureJosephine Harrington, Jie-Lena Sun, Gregg C Fonarow, et al.
The Canadian Journal of Cardiology|June 25, 2019
Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF TrialStephen J Greene, G Michael Felker, Anna Giczewska, et al.
The American Journal of Cardiology|January 22, 2022
Low Blood Pressure Threshold for Adverse Outcomes During Left Ventricular Assist Device SupportHimabindu Vidula, Onur Altintas, Scott McNitt, et al.
JACC. Heart Failure|December 14, 2020
Heart Failure Hospitalization and Guideline-Directed Prescribing Patterns Among Heart Failure With Reduced Ejection Fraction PatientsPratyaksh K Srivastava, Adam D DeVore, Anne S Hellkamp, et al.
European Journal of Heart Failure|February 15, 2017
Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trialAdam D DeVore, Steven McNulty, Fawaz Alenezi, et al.
Pageof 34

Showing results (231-240 of 339) with videos related to

Sort By:
Pageof 34
Journal of Cardiac Failure|November 18, 2021
Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF RegistryStephen J Greene, Javed Butler, Anne S Hellkamp, et al.
Journal of Cardiac Failure|January 24, 2025
Implantable Cardioverter-Defibrillators and Cardiovascular Resynchronization Therapy with Left Ventricular Assist DevicesA MOMENTUM 3 Trial AnalysisGabriel Sayer, Mustafa M Ahmed, Mandeep R Mehra, et al.
American Heart Journal|January 26, 2021
Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbiditiesNancy M Albert, Rachel J Tyson, C Larry Hill, et al.
Journal of the American Heart Association|June 20, 2022
Angiotensin Receptor Neprilysin Inhibition and Associated Outcomes by Race and Ethnicity in Patients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP-HFBrittany Chapman, Anne S Hellkamp, Laine E Thomas, et al.
American Heart Journal|August 10, 2016
Development and validation of a risk model for in-hospital worsening heart failure from the Acute Decompensated Heart Failure National Registry (ADHERE)Adam D DeVore, Melissa A Greiner, Puza P Sharma, et al.
The American Journal of Cardiology|September 4, 2023
Potential Applicability of Omecamtiv Mecarbil to Patients Hospitalized for Worsening Heart FailureJosephine Harrington, Jie-Lena Sun, Gregg C Fonarow, et al.
The Canadian Journal of Cardiology|June 25, 2019
Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF TrialStephen J Greene, G Michael Felker, Anna Giczewska, et al.
The American Journal of Cardiology|January 22, 2022
Low Blood Pressure Threshold for Adverse Outcomes During Left Ventricular Assist Device SupportHimabindu Vidula, Onur Altintas, Scott McNitt, et al.
JACC. Heart Failure|December 14, 2020
Heart Failure Hospitalization and Guideline-Directed Prescribing Patterns Among Heart Failure With Reduced Ejection Fraction PatientsPratyaksh K Srivastava, Adam D DeVore, Anne S Hellkamp, et al.
European Journal of Heart Failure|February 15, 2017
Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trialAdam D DeVore, Steven McNulty, Fawaz Alenezi, et al.
Pageof 34